A case of imatinib-related obstructive bronchiolitis followed long term

Chika Yajima; Nariaki Kokuho; Kazutoshi Toriyama; Junichiro Kawagoe; Yuki Togashi; Jun Matsubayashi; Hideaki Nakayama; Yasuhiro Setoguchi; Shinji Abe

doi:10.1016/j.rmcr.2020.101052

A case of imatinib-related obstructive bronchiolitis followed long term

Respir Med Case Rep. 2020 Apr 4:30:101052. doi: 10.1016/j.rmcr.2020.101052. eCollection 2020.

Authors

Chika Yajima¹, Nariaki Kokuho¹, Kazutoshi Toriyama¹, Junichiro Kawagoe¹, Yuki Togashi¹, Jun Matsubayashi², Hideaki Nakayama¹, Yasuhiro Setoguchi³, Shinji Abe¹

Affiliations

¹ Department of Respiratory Medicine, Tokyo Medical University, Tokyo, Japan.
² Department of Pathology, Tokyo Medical University, Tokyo, Japan.
³ Tokyo Medical and Dental University, Tokyo, Japan.

Abstract

Obstructive bronchiolitis (OB) is an intractable disease causing stenosis in the surrounding bronchiolar region and bronchiolar lumen obstruction. Causes of OB are lung and hematopoietic stem-cell transplantation, collagen diseases, infections, and foods, but there are very few reports of drug-induced OB [1]. Imatinib is a drug used for the treatment of leukemia, gastrointestinal stromal tumors, etc. Although there are some reports of imatinib-induced lung injury as a complication (Ohnishi et al., 2006; Ma et al., 2003; Yamasawa et al., 2008; Koide et al., 2011) [[2], [3], [4], [5]], OB has not been reported. We have encountered a patient with OB related to imatinib administered for chronic myelogenous leukemia, who we have followed for 10 years. Drug-induced OB is very rare, but our case demonstrates the importance of considering the possibility of airway lesions by evaluating pulmonary function and expiratory computed tomography in patients with respiratory symptoms despite no shading on imaging.

Keywords: Drug-induced OB; Drug-induced lung injury; Imatinib; Nilotinib; Obstructive bronchiolitis (OB).

Publication types

Case Reports